Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Betaseron: Marketed

Berlex and manufacturing partner Chiron Corp. (CHIR, Emeryville, Calif.) said that Betaseron reduced the development of hypointense T1 lesions,

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE